SCHEMBL4998259

SCHEMBL4998259

COc1ccc2c(c1)CN(C(=O)Oc1ccc(N3CCC(C)(C)CC3=O)cn1)CC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 7/20 0.41
ABHD6 Q9BV23 1/20 0.40
HRH1 P35367 1/20 0.40
ACHE P22303 1/20 0.40
CHRM4 P08173 2/20 0.40
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
LIPE Q05469 1/20 0.39
SPR P35270 1/20 0.38
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
AKR1C3 P42330 1/20 0.37
ROCK1 Q13464 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PORCN Q9H237 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4998517 0.97 ABHD6 (0.44) HRH3ABHD6HRH1ACHECHRM4
SCHEMBL4996224 0.90 GRM5 (0.40) HRH3HRH1ACHECHRM4LIPE
SCHEMBL4989335 0.90 KMT2A (0.42) ALDH1A1HPGD
SCHEMBL4998738 0.89 GRM5 (0.38) HRH3HRH1ACHECHRM4LIPE
SCHEMBL14073070 0.89 ABHD6 (0.42) HRH3ABHD6ACHECHRM4ESR1
SCHEMBL5002110 0.88 LIPE (0.46) ABHD6ACHELIPEALDH1A1HPGD
SCHEMBL4989312 0.86 GRM5 (0.40) HRH3ABHD6HRH1ACHECHRM4
SCHEMBL5004384 0.85 GRM5 (0.38) HRH3HRH1ACHECHRM4ESR2
SCHEMBL14073072 0.85 ABHD6 (0.46) HRH3ABHD6HRH1ACHECHRM4
SCHEMBL4998513 0.83 ABHD6 (0.40) HRH3ABHD6HRH1ACHECHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227792-A1 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters NOVO NORDISK A/S (DK) 2008-09-18 US claimed
US-20080227792-A1 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters NOVO NORDISK A/S (DK) 2008-09-18 US disclosed
EP-1853585-A1 3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID 5-AMINOPYRIDIN-2-YL ESTERS Novo Nordisk A/S (DK) 2007-11-14 EP disclosed
WO-2006087309-A1 3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID 5-AMINOPYRIDIN-2-YL ESTERS NOVO NORDISK A/S (DK) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227792-A1 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters LIPE, LIPC, PNLIP HRH3 1272/4885ABHD6 74/4885HRH1 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.